Skip to content

DR. ROSSEEL - DR. WESTERLINCK

Active Private limited companyfounded 2005active for 21 yearsDiestersteenweg 418, 3680 MaaseikKBO/BCE: BE 0871.031.294

Lifetime

20 annual accounts with figures on one time axis, 21 filings since 2005
peak of €444,271 in 2025
€444,271▲ 12.2%
peak of €359,305 in 2025
€359,305▲ 23.1%
peak of €1.4m in 2025
€1.4m▲ 22.1%
€172,716▼ 39.4%
peak of 1 FTE in 2006
-not published
Board2 names since 2021
2 directors and 1 other
Owners2 names in the annual accounts
  
Documentsfilings and deeds
30-06-202631 days before the deadline
2025micro format
Gross margin from €396,112 to €444,271Dividend €111,100Equity from €1.1m to €1.4mDebts from €285,026 to €172,716Investments €54,131

Key points

from the 2025 annual accounts

Equity

€1.4m ▲ 22.1%

DR. ROSSEEL - DR. WESTERLINCK has made a profit in every financial year since 2006.

Investments

€54,131 4.4 times depreciation

Green is investment, beige is depreciation.

Filings

21 annual accounts since 2005
AprilJune31 JulyOctober20052010201520202025

The last five annual accounts were filed 28 to 31 days before the end of the period.

Checked score

Bankruptcy probability within 12 months

Financial strength

Score breakdown

Comparable companies, two years later

In July 2024, 20,149 companies had the same profile as DR. ROSSEEL - DR. WESTERLINCK has now. Each dot stands for 51 companies, two years later.

95.0%
were still trading
4.7%
stopped another way
0.2%
went bankrupt
  • Small
  • 20 years or older
  • solvency 30% or more
  • a profit of 5% of the balance sheet or more
Test of the method

The method was tested on the 497,962 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.

The companies in ten equal groups, from the lowest to the highest expected share
Group Expected Actual
1 0.2% 0.2%
2 0.3% 0.5%
3 0.5% 0.6%
4 0.7% 0.8%
5 0.9% 0.9%
6 1.3% 1.5%
7 1.6% 1.8%
8 1.8% 1.8%
9 2.9% 3.1%
10 5.6% 6.1%

A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.

This is an observation about 20,149 companies, not a prediction for DR. ROSSEEL - DR. WESTERLINCK. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.

Credit verdict

Credit check for an amount and term of your choice

Show the recommended maximum and see how the verdict changes with amount, term and advance.

The scores and ratios are Checked's own calculations, not a credit decision.

Signals

Board and ownership

Director
Director
  • 50%annual accounts 2017
  • 50%annual accounts 2017
Board & ownership

Recent changes

Registered in the Peppol Directory Reachable for e-invoices through 0208:0871031294
2 managers resigning, 2 directors reappointed (director, formerly manager) and (director, formerly manager) resign · (director) and (director) reappointed · “De uitoefening van de geneeskunde met specialisatie neus-, keel- en oorziekten, hetzij anesthesie, door de…” (deed in Dutch) · General meeting of 29-11-2022 · Gazette deed
Capital decrease of €314,100 to €18,600 The capital fell from €332,700 to €18,600 · General meeting of 20-03-2018 · Gazette deed
Capital increase of €314,100 to €332,700 The capital rose from €18,600 to €332,700 · holds all the shares · General meeting of 20-12-2013 · Gazette deed
All 34 events

Official details

Source: KBO
Status
Active since 06-01-2005Normal situation
Activity
“De uitoefening van de geneeskunde met specialisatie neus-, keel- en oorziekten, hetzij anesthesie, door…” (deed in Dutch)From the articles, 7 activities1 activities on the establishment units
Establishment units
2.229.215.9903680 Maaseik, since 23-12-2004
2.229.216.2873960 Bree, since 01-01-2005
Financial year end
31 December
Peppol
Reachable since 01-12-2025
Company details

Annual accounts 2025

≈ €890,000estimated
€1.5m▲ 9.6%
Filing
Filed on 30-06-2026, 31 days before the end of the filing period
Financials

Insights on DR. ROSSEEL - DR. WESTERLINCK

DR. ROSSEEL - DR. WESTERLINCK files the micro format. That format states no turnover. The gross margin rose from €278,239 in 2006 to €444,271 in 2025.

Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.

Key facts about DR. ROSSEEL - DR. WESTERLINCK

What is the company number of DR. ROSSEEL - DR. WESTERLINCK?
The company number of DR. ROSSEEL - DR. WESTERLINCK is 0871.031.294. The VAT number is the same number with BE in front: BE 0871.031.294.
Where is DR. ROSSEEL - DR. WESTERLINCK based?
The registered office is at Diestersteenweg 418, 3680 Maaseik.Company details
What is the legal form of DR. ROSSEEL - DR. WESTERLINCK?
DR. ROSSEEL - DR. WESTERLINCK is a private limited company (BV).
When was DR. ROSSEEL - DR. WESTERLINCK founded?
DR. ROSSEEL - DR. WESTERLINCK was founded on 06-01-2005.
Is DR. ROSSEEL - DR. WESTERLINCK still active?
Yes, DR. ROSSEEL - DR. WESTERLINCK is an active enterprise in the KBO register.
What is the turnover of DR. ROSSEEL - DR. WESTERLINCK?
The turnover in financial year 2025 is ≈ €890,000. This figure is estimated from the gross margin of €444,271 and 1,019 comparable companies of the same size. It probably lies between €620,000 and €1.3m. It is a rough estimate.Financials
Is DR. ROSSEEL - DR. WESTERLINCK profitable?
In financial year 2025, DR. ROSSEEL - DR. WESTERLINCK made a profit of €359,305.
Where can I find the annual accounts of DR. ROSSEEL - DR. WESTERLINCK?
DR. ROSSEEL - DR. WESTERLINCK filed 21 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
When are the next annual accounts of DR. ROSSEEL - DR. WESTERLINCK due?
DR. ROSSEEL - DR. WESTERLINCK must file the annual accounts for financial year 2026 by 31-07-2027.Timeline

Next steps

See how customers, suppliers and banks see your own company and what to improve first.

Keep this company with today's facts in a case file.